Proteome Of Australia Becomes Tyrian Diagnostics
This article was originally published in PharmAsia News
Executive Summary
Australia's Proteome System, which said in August it would quit the drug-development business, has changed its name to Tyrian Diagnostics and become a maker or biomarker diagnostics. The firm said in August it would close its drug-development business along with its office in the United States. Tyrian Diagnostics said the new name is intended to reflect the new emphasis on diagnostics. CEO Jenny Harry said the decision to leave the therapeutic business allowed the firm to make the switch. (Click here for more
Australia's Proteome System, which said in August it would quit the drug-development business, has changed its name to Tyrian Diagnostics and become a maker or biomarker diagnostics. The firm said in August it would close its drug-development business along with its office in the United States. Tyrian Diagnostics said the new name is intended to reflect the new emphasis on diagnostics. CEO Jenny Harry said the decision to leave the therapeutic business allowed the firm to make the switch. (Click here for more) "Shifting To Biomarkers, Proteome Systems Changes Name To Tyrian Diagnostics" - GenomeWeb Daily News (U.S.) (11/14/08) |